Annual report pursuant to Section 13 and 15(d)

Discontinuing Operations - Reconciliation of the original gross sales price (Details)

v3.21.1
Discontinuing Operations - Reconciliation of the original gross sales price (Details) - BioPharma Disposal - USD ($)
$ in Thousands
Oct. 24, 2019
Jul. 15, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Gross sales price   $ 23,500
Adjustments to sales price:    
Consideration received $ 153  
Discontinuing Operations    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Gross sales price   23,500
Adjustments to sales price:    
Transaction costs   (1,525)
Working capital adjustments   (2,705)
Payment of other expenses   (171)
Total adjustments to sales price   (4,401)
Consideration received   $ 19,099